|
|
|
|
|
|
|
|
130th MAINE LEGISLATURE |
|
|
LD 1117 |
|
LR 1071(02) |
|
|
|
An Act To Prevent
Excessive Prices for Prescription Drugs |
|
Fiscal Note for
Bill as Amended by Committee Amendment " " |
|
Committee: Health Coverage, Insurance and
Financial Services |
|
Fiscal Note Required: Yes |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fiscal Note |
|
|
|
|
|
|
|
Current biennium revenue increase - General Fund
Minor cost increase - Other Special Revenue Funds
Minor revenue increase - Other Special Revenue Funds |
|
|
|
|
|
|
|
Correctional
and Judicial Impact Statements |
|
|
|
|
|
This bill may
increase the number of civil suits filed in the court system.
The additional workload associated with the minimal number of new cases
filed in the court system does not require additional funding at this time.
The collection of additional filing fees may increase General Fund and
other dedicated revenue by minor amounts. |
|
|
|
|
|
|
|
Fiscal Detail
and Notes |
|
|
|
|
|
|
Upon an action
brought by the Office of the Attorney General (OAG) in Superior Court, a
civil penalty of $500,000 may be assessed against any prescriptin drug
manufacturer for certain violations. It is anticipated that the new and
increased penalty will increase revenues to the General Fund and will depend
on the number of violations. |
|
Any additional
costs to the OAG and the Maine Health Data Organization are expected to be
minor and can be absorbed within existing budgeted resources. |
|
|
|
|
|
|
|